Insider Purchases: Inside the Buy

Tag: oncology stocks

A biotech battlefield. In the foreground, a determined biotech researcher carries a glowing dual-target antibody labeled

🫁 Summit Therapeutics (SMMT): The Keytruda Challenger, the Insider Buying Spree, and the November FDA Showdown

Summit Therapeutics may be one of biotech's most fascinating high-risk, high-reward stories. Ivonescimab is taking aim at Keytruda, insiders keep buying shares, short interest remains elevated, and a major FDA decision looms in November 2026.

Read entire article

Tags: Baker Brothers, BiotechStocks, buy or sell SMMT, cancer research, FDA approval, featured-insiders, FUNanc1al, FunStock, GARP, healthcare investing, hub-insiders, immunotherapy, insider buying, InsiderBuying, ivonescimab, Keytruda, lung cancer, oncology stocks, PDUFA, risks buying SMMT, Robert Duggan, short squeeze, ShortSqueeze, SMMT, Summit Therapeutics, SummitTherapeutics, ValueInvesting, why buy SMMT
Digital illustration of a cancer cell being zapped by electric fields, symbolizing Novocure’s Tumor Treating Fields and stock rebound hopes.”

Novocure (NVCR): From Electric Fields to Fighting Cancer — and Maybe Lifting Portfolios?

Novocure is zapping cancer cells with Tumor Treating Fields — and maybe giving investors a shock of opportunity. With insiders and institutions piling in, can NVCR rebound 94% from its crash? ⚡📈

 

Read entire article

Tags: Ashley Cordova, Biotech Investing, BiotechGrowth, CEO Ashley Cordova, CEO Buys, CEO Conviction, CEO insider buying, CEO Stock Purchase, CEOBuyIn, CEOConfidence, CFO Bought Shares, CFO Insider Buying, CFOBuyIn, Funanc1al Humor, funanc1al investing, Funanc1al Stocks, glioblastoma, high-risk biotech, high-risk high-reward biotech, insider buying, institutional investors, Novocure, NVCR stock, oncology stocks, pancreatic cancer, tumor treating fields